Microdeformational wound therapy: Effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients

Annals of Plastic Surgery

Volumn 56, Issue 4, 2006, Pages 418-422

  Greene, Arin K ^a   Puder, Mark ^b   Roy, Roopali ^b   Arsenault, Danielle ^b   Kwei, Stephanie ^a   Moses, Marsha A ^b   Orgill, Dennis P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Matrix metalloproteinases; MDWT; Microdeformational wound therapy; Subatmospheric pressure; VAC; Vacuum assisted closure; Wound healing

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CASE REPORT; CHRONIC WOUND; DENSITY; DEVICE; ENZYME ACTIVITY; FEMALE; FOAM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICRODEFORMATIONAL WOUND THERAPY; MICROVASCULATURE; PRIORITY JOURNAL; THERAPY; VACUUM ASSISTED CLOSURE; ZYMOGRAPHY;

AGED; ANTIGENS, CD31; BIOPSY; CAPILLARIES; CELL COUNT; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; RECONSTRUCTIVE SURGICAL PROCEDURES; WOUND HEALING; WOUNDS AND INJURIES;

EID: 33645383793     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sap.0000202831.43294.02     Document Type: Article

References (35)

1. Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method of wound control and treatment: clinical experience. Ann Plast Surg. 1997;38:563-576.
2. Morykwas MJ, Argenta LC, Shelton-Brown EI, et al. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. Ann Plast Surg. 1997;38:553-562.
3. Joseph E, Hamori CA, Bergman S, et al. A prospective randomized trail of vacuum-assisted closure versus standard therapy of chronic nonhealing wounds. Wounds. 2000;12:60-67.
4. McCallon SK, Knight CA, Valiulus JP, et al. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage. 2000;46:28-32.
5. Edington MT, Brown KR, Seabrook BR, et al. A prospective randomized evaluation of negative pressure wound dressing for diabetic foot wounds. Ann Vasc Surg. 2003;17:645-649.
6. Saxena V, Hwang CW, Huang S, et al. Vacuum-assisted closure: microdeformations of wounds and cell proliferation. Plast Reconstr Surg. 2004;114:1086-1096.
7. Folkman J, Moscona A. Role of cell shape in growth control. Nature. 1978;273:345-349.
8. Chen CS, Mrksich M, Huang S, et al. Geometric control of cell life and death. Science. 1997;276:1425-1428.
9. Huang S, Ingber DE. The structural and mechanical complexity of cell-growth control. Nat Cell Biol. 1999;5:E131-E138.
10. Chen SZ, Li J, Li XY, et al. Effects of vacuum-assisted closure on wound microcirculation: an experimental study. Asian J Surg. 2005;28:211-217.
11. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res. 2003;9:551-554.
12. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al. Regulation of angiostatin production by matrix metalloprotienase-2 in a model of concomitant resistance. J Biol Chem. 1999;274:29568-29571.
13. Moses MA, O'Reilly MS. Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2. Methods Mol Med. 2003;74:375-390.
14. Tarlton JF, Vickery CJ, Leaper DJ, et al. Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase-9. Br J Dermatol. 1997;137:506-516.
15. Chen C, Schultz GS, Bloch M, et al. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds. Wound Repair Regen. 1999;7:486-494.
16. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993;101:64-68.
17. Ladwig GP, Robson MC, Liu R, et al. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 2002;10:26-37.
18. Lerman OZ, Galiano RD, Armour M, et al. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol. 2003;162:303-312.
19. Greene AK, Alwayn I, Nose V, et al. Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann Surg. 2005;242:140-146.
20. Peters CA, Freeman MR, Fernandez CA, et al. Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. Am J Physiol. 1997;272:1960-1965.
21. Harrington C, Zagari MJ, Corea J, et al. Cost analysis of diabetic lower-extremity ulcers. Diabetes Care. 2000;23:1333-1338.
22. Venturi ML, Attinger CE, Mesbahi AN, et al. Mechanisms and clinical applications of the vacuum-assisted closure (VAC) device: a review. Am J Clin Dermatol. 2005;6:185-194.
23. Ailawadi M, Lee JM, Lee S. Adenovirus vector-medicated transfer of the vascular endothelial growth factor cDNA to healing abdominal fascia enhances vascularity and bursting strength in mice with normal and impaired wound healing. Surgery. 2002;131:219-227.
24. Romano DS, Mangoni A, Zambruno G, et al. Adenovirus-mediated VEGF (165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther. 2002;9:1271-1277.
25. Yang GP, Lim IJ, Phan TT, et al. From scarless fetal wounds to keloids: molecular studies in wound healing. Wound Repair Regen. 2003;11:411-418.
26. Detmar M, Brown LF, Berse B, et al. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF) and its receptors in human skin. J Invest Dermatol. 1997;108:263-268.
27. Korff T, Augustin HG. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci. 1999;112:3249-3258.
28. Nagal T, Resnick N, Dewey CF, et al. Vascular endothelial cells respond to spatial gradients in fluid shear stress by enhanced activation of transcription factors. Arterioscler Thromb Vasc Biol. 1999;19:1825-1834.
29. Yan L, Moses MA, Huang S, et al. Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci. 2000;113:3979-3987.
30. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 1998;161:6845-6852.
31. Pozzi A, Moberg PE, Miles LA, et al. Elevated matrix metalloproteinase and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A. 2000;29:2202-2207.
32. Pozzi A, Levine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene. 2002;21:272-281.
33. Ulrich D, Lichtenegger F, Unglaub F, et al. Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro. Plast Reconstr Surg. 2005;116:539-545.
34. Moses MA, Marikovsky M, Harper JW, et al. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem. 1996;60:379-386.
35. Greene AK, Puder M, Roy R, et al. Urinary matrix metalloproteinases and their endogenous inhibitors predict hepatic regeneration after murine partial hepatectomy. Transplantation. 2004;78:1139-1144.